Guselkumab

A fully human monoclonal antibody that selectively inhibits interleukin-23 by targeting its p19 subunit, used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis. It reduces the inflammatory cascade driven by IL-23 that causes the accelerated skin cell turnover characteristic of psoriasis. Patients typically receive injections every eight weeks after an initial loading phase.

Yes, Guselkumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.